NEW HAVEN, Conn., March 17, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q4 and year end 2024 corporate update call on March 31 st , 2025 at 5:00 PM ET. The call will include updates on all of the company’s current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask... Read More

NEW HAVEN, Conn., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that it has achieved two important financial goals in the last quarter of 2024: Positive Adjusted EBITDA – Precipio reports (unaudited) A djusted EBITDA of $0.4 M for Q4-2024. Adjusted EBITDA is a non-GAAP metric that comprises EBITDA, less non-cash stock-based compensation expense and other... Read More

NEW HAVEN, Conn., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that options granted to senior management on January 14 would vest when the 10-day VWAP of the Company’s common stock exceeds $30.30 per share – a level 5x greater than the option exercise price, the closing price from Tuesday, January 14. These options have no time-based vesting; if the... Read More

Conference Call to be held on November 18, 2024, at 5:00 PM EST NEW HAVEN, Conn., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q3-2024 corporate update call on November 18 th at 5:00 PM ET. The call will provide commentary on Precipio's Q3-2024 10-Q filed today, including financial highlights and analysis of the company's core businesses. The... Read More

NEW HAVEN, Conn., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the launch of a new version of its Bloodhound MPN (Myeloproliferative Neoplasm) panel that is now able to distinguish between CALR type 1 and type 2 mutations. The CALR mutation data plays a critical role in disease prognosis and therapeutic decision-making. This differentiation aligns with the... Read More

NEW HAVEN, Conn., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the Company’s repricing of a portion of its employee stock options to ensure their effectiveness as a retention tool for valuable employees. Management is confident that the practical, strategic, and economic benefit to shareholders will ultimately be positive. Retaining valuable employees in an... Read More

NEW HAVEN, Conn., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q2-2024 corporate update call on August 19 th at 5:00 PM ET. The call will include updates on the company’s current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio Inc.... Read More

NEW HAVEN, Conn., July 25, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that its unaudited non-GAAP Cash Burn/Generated from Operations (CBFO) for Q2-2024 was $0.3M of cash generated for the quarter. It is important to note that a small contributing factor to the cash increase was the incoming cash collections that were expected in Q1, but were delayed and received in... Read More

NEW HAVEN, Conn., July 17, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that for Q2-2024, its unaudited revenues have grown from $3.4M in Q1-2024 to $4.4M in Q2-2024, an increase of 30% from one quarter ago. Pathology Division revenue in June reached its breakeven point, and the company anticipates continued growth in the next few months. We expect this division’s... Read More

NEW HAVEN, Conn., June 13, 2024 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced that the company’s 2024 Annual Meeting of Shareholders (“Annual Meeting”) was convened and adjourned, without any business being conducted, due to lack of the required quorum. Message from Ilan Danieli, CEO: During this process, we’ve realized that there are quite a few shareholders who didn’t know... Read More

NEW HAVEN, Conn., June 12, 2024 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) is requesting that shareholders instruct their brokers to vote their shares immediately today no later than 11pm Eastern Time. In order to ensure that there is a quorum required for the shareholders’ meeting that is scheduled to take place tomorrow June 13, 2024 at 10 a.m. Eastern Time. At the... Read More

NEW HAVEN, Conn., June 12, 2024 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) provides the following update to its shareholders on various business matters looking towards mid-year. 1. Business growth In September of 2023, Precipio’s pathology division exceeded its breakeven point of $15M annualized revenue run rate, resulting in a Q4 cash burn of less than $100K for the... Read More

NEW HAVEN, Conn., May 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces it has secured a short-term loan facility of $500K to deal with any delays in cash collections due to the recent cybersecurity attack on Change Healthcare , a healthcare billing company used by a significant part of the healthcare market. Many healthcare businesses, including Precipio’s Diagnostic... Read More

NEW HAVEN, Conn., March 25, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its year end 2023 corporate update call on April 1 st , 2024 at 5:00 PM ET. The call will include updates on all of the company’s current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the... Read More

NEW HAVEN, Conn., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. ( NASDAQ: PRPO), announces that for the full year of 2023, its unaudited revenues have grown from $9.4M in 2022 to $15.2M in 2023, an increase of 60% year over year. Both pathology and products divisions have demonstrated substantial growth from 2023, with the pathology services division increasing revenue by 52%, and the... Read More

NEW HAVEN, Conn., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces it has entered into a distribution agreement with Cardinal Health for its HemeScreen molecular assay products. Under the agreement, Cardinal Health will market and distribute Precipio’s HemeScreen portfolio of molecular assays to its customer base, which comprises primarily the acute healthcare... Read More

NEW HAVEN, Conn., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces that continued revenue growth generated cash levels that bring the company closer to breakeven. Cash Burn From Operations (CBFO) declined by over 90% from the previous quarter, from approximately $1M/quarter in Q3-2023 to below $100k/quarter in the following recent quarter Q4-2023. Precipio’s end... Read More

NEW HAVEN, Conn., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces it has entered into an agreement with a Japanese distributor for the sales and distribution of its products into the Japanese market. The distributor has already secured its first purchase order from a leading Japanese clinical laboratory, for Precipio’s proprietary IV-Cell cytogenetics media. The... Read More

NEW HAVEN, Conn., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) is pleased to welcome Christina Valauri to its board of directors effective Jan 1st, 2024. Ms. Valauri is joining Precipio’s board to support management’s understanding of and interaction with the capital markets, as we look towards 2024 to be an important period for our company from both a business growth,... Read More

NEW HAVEN, Conn., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) shares thoughts and reflections looking back at 2023, and forward to 2024. At the start of 2023, management set three goals, all focused on achieving cash flow breakeven going forward: Target #1: For the pathology division, reaching estimated annualized revenues of $14M, which was expected to... Read More

NEW HAVEN, Conn., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q3-2023 corporate update call on November 20 th , 2023 at 5:00 PM ET. The call will include updates on all of the company’s current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the... Read More

NEW HAVEN, Conn., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that Q3-2023 (unaudited) revenues have increased 28% to $4.5M from $3.5M in Q2-2023, and have more than doubled from $2.2M from Q3-2022. The combination of ongoing revenue growth in both the pathology and products divisions, alongside efficiency and cost reduction initiatives has rapidly moved the... Read More

NEW HAVEN, Conn., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that the combination of revenue growth and cost cutting initiatives has reduced Cash Burn From Operations (CBFO) by 59% compared to the same quarter last year, from approximately $2.5M/quarter to $1M/quarter. Management has set a target of reaching financial independence with its current cash... Read More

NEW HAVEN, Conn., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced that new customer orders are expected to bring total Q4 HemeScreen revenues to an estimated $1.2M. In a recent announcement , the company announced that the product revenue necessary to reach cash flow breakeven has been reduced to $6M annualized run rate, or $1.5M/quarter. As of today, Precipio... Read More

NEW HAVEN, Conn., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced that due to the increased pathology revenue, and the recent operational efficiencies, the company has reduced the revenue required from the products division to reach breakeven from $8M to $6M annually, or $1.5M per quarter, 25% below previous estimates. This means that the company anticipates... Read More

NEW HAVEN, Conn., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) today announced that it has implemented a 1-for-20 reverse stock split of outstanding shares of the company's common stock in order to regain compliance with the Nasdaq minimum bid price requirement of $1.00. What is the economic impact to you, the shareholder? A reverse split essentially means a decrease... Read More

NEW HAVEN, Conn., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces its Pathology Division has in August exceeded the monthly breakeven revenue goal which, if continued, causes this division to contribute cash to the Company’s operations. As previously announced, the revenue target for pathology division breakeven is an annualized run rate of $14M, which is... Read More

NEW HAVEN, Conn., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q2-2023 corporate update call on August 17 th at 5:00 PM ET. The call will include updates on all of the company’s current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio... Read More

NEW HAVEN, Conn., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces the launch of its new quantitative BCR-ABL 2.0 panel, with features making it the most innovative panel of its kind on the market. For more information on this new panel please visit us at https://tinyurl.com/QBCR-ABL1 . Patients with Chronic Myeloid Leukemia (CML) have cells which contain an... Read More

NEW HAVEN, Conn., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces significant reductions in its cash-burn. For the six months ended June 30, 2023, Precipio is projected to report cash burn (excluding financing proceeds) of $3.1M, a reduction of $1.1M from $4.2M for the same period in 2022, or 26% reduction YoY. Q2-2023 cash burn has declined to $1.4M from $1.7M... Read More

NEW HAVEN, Conn., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that Q2-2023 revenues have increased to $3.5M in Q2-2023 from $2.8M in Q1-2023, an increase of 25% QoQ. The following factors contribute to the Company’s path to breakeven: Growth rates of each division: The Company's revenues derived from the products division grew 15%, and the revenues from the... Read More

NEW HAVEN, Conn., June 14, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. leveraged its proprietary HemeScreen Cytopenia panel as part of the diagnostic process for molecular identification of driver mutations in a patient with a history of transfusion-dependent anemia and experiencing progressive weakness and neurological symptoms. The findings point to an underlying myeloid stem cell disorder,... Read More

NEW HAVEN, Conn., June 13, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. ( NASDAQ: PRPO), announces that it has entered into a collaboration agreement with a NY-based academic healthcare institution to jointly develop a panel for Glioblastoma (GBM), an aggressive brain cancer based on Precipio’s HemeScreen technology. Precipio will design and develop a panel that combines a select number of... Read More

NEW HAVEN, Conn., June 08, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced it has entered into securities purchase agreements with certain institutional investors for the purchase and sale of 4,125,000 shares of the Company’s common stock and pre-funded warrants to purchase 319,445 shares of the Company’s common stock in a registered direct offering and warrants to... Read More

NEW HAVEN, Conn., June 07, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. ( NASDAQ: PRPO), announces that several operational improvement initiatives which commenced at the start of the year have begun to impact the cash burn and bottom line profitability. These operational efficiency improvements are independent of the contribution that the revenue continues to provide to the Company. While the... Read More

NEW HAVEN, Conn., May 22, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. leveraged its proprietary HemeScreen technology as part of the diagnostic process to monitor a patient with a history of Chronic Myeloid Leukemia (CML) and p210 isoform expression which allowed the lab to uncover an additional oncogene isoform expression (p190). While many labs only monitor previously detected mutations for... Read More

NEW HAVEN, Conn., May 17, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be discussing on today’s shareholders call several growth catalysts that management has been tracking. The Company believes that these catalysts could serve as positive indicators of future growth for HemeScreen revenues. Distributor rep engagement increased from 16% to 37% One of the many benefits of... Read More

NEW HAVEN, Conn., May 15, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q1-2023 corporate update call on May 17 th at 5:00 PM ET. The call will include updates on all of the company’s current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio Inc.... Read More

NEW HAVEN, Conn., May 04, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces another agreement with a new pathology services customer to utilize Precipio’s diagnostic services. Based on the customer’s size and expected volume, with the addition of this and other customers, Precipio anticipates that with the addition of this customer, the Company expects to reach... Read More

NEW HAVEN, Conn., May 04, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces another agreement with a new customer to bring HemeScreen™ technology into their laboratory. With each additional customer, Precipio continues to execute on its strategy, converting pipeline prospects to actual customers, and progressing towards breakeven. The company incurs virtually no additional... Read More

NEW HAVEN, Conn., April 27, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces notification by the NASDAQ Stock Market that the Company has been granted a 180-day extension to allow the Company to meet the required minimum $1.00 per share closing bid price of its common stock for 10 consecutive business days for continued inclusion on the Nasdaq Capital Market Exchange.... Read More

NEW HAVEN, Conn., April 19, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that Q1-2023 product revenues have surpassed product revenues during the two prior quarters of 2022, and exceed 50% of the entire year of 2022 product revenues of $1.4M. This equals a current annualized run rate of $3M, which is more than double the total product revenues for 2022. This... Read More

NEW HAVEN, Conn., March 28, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q4-2022 and year end shareholder update call on Monday, April 3 rd at 5:00 PM ET. The call will include updates on the Company’s current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for... Read More

NEW HAVEN, Conn., March 21, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) delivered its first order of IV-Cell ® , the Company’s proprietary cytogenetics cell culturing media, to a major US healthcare system. The healthcare system (unnamed for competitive reasons) has successfully completed the validation of the media and will begin the gradual incorporation into clinical use.... Read More

NEW HAVEN, Conn., March 07, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) continues to convert its sales pipeline into HemeScreen customers, with an additional recently signed agreement expected to generate annualized revenues exceeding $125,000. Furthermore, this month we also expect another customer to launch an additional new panel within their lab, growing their internal... Read More

NEW HAVEN, Conn., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) was recognized at ThermoFisher’s National Sales Meeting for the development and launch of its HemeScreen ® technology. HemeScreen is distributed by Fisher Healthcare, a division of ThermoFisher, to... Read More

NEW HAVEN, Conn., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced another 4-year agreement with a new customer to bring HemeScreen™ technology into their laboratory. Based on the customer’s expected patient volume, with the addition of this customer, revenues in Q1-2023 are now estimated to be approximately 200% greater than Q1-2022, and the quarterly run rate... Read More